Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients.

Abstract

MBL is an aggressive NHL with unique clinicopathologic aspects, often refractory to current CHT designed for high-grade NHL. Poor performance status and pericardial effusion predict NR and poor survival. Inadequate response after the first courses of front-line CHT predicts failure of subsequent treatment. Responders with bulky mediastinum or residual mediastinal abnormality after CHT are at risk of relapse. These factors should help to select high-risk patients for intensive treatments.

Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma

“…9,[15][16][17] It is characterized clinically by aggressive tumor growth in the mediastinum with frequent lung involvement and a tendency when disseminated to involve extranodal sites. 16 Histologically it comprises large tumor cells with abundant pale cytoplasm, and it has been noted that the morphology of these cells and the presence in some cases of a sclerotic background are features reminiscent of classical Hodgkin's disease (which also often involves the mediastinum). 9,18 However, other aspects of Hodgkin's disease (eg an inflammatory eosinophil-rich infiltrate) are lacking.…”

Primary mediastinal B‐cell lymphoma

“…The majority of events occur within the first 12 months, and are rare beyond 2 years from completion of therapy, 43,44,47,76 and every effort should be made to confirm histology at the time of recurrence and not to rely on functional imaging alone. Salvage therapy of PMBL has followed that of DLBCL, attempting reinduction with non-crossresistant agents, followed by consolidation with high-dose chemotherapy in those deemed fit enough.…”

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care

“…In contrast to DLBCL, which accounts for 30% of all cases of non-Hodgkin's lymphoma, PMLBCL is rare, representing only 2.5% of cases [2]. PMLBCL is characterized by distinctive morphologic, demographic, and clinical features [1][2][3][4]. It affects mainly young patients (median age, 30 -35 years), with a female predominance, and is very rare in patients aged Ͼ60 years.…”